A Typology of Communication Dynamics in Families Living a Slow-Motion Technological DisasterTreatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition).Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group.Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.Extrapulmonary and pulmonary small-cell carcinoma: tumor biology, therapy, and outcome.Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancer patients and their family caregiversQuantitative and qualitative analysis of human lymphocyte proliferation to specific antigen in vitro by use of the helium neon laser.Application of laser cytometry to the analysis of immunologically induced in vitro lymphocyte responsiveness.Community-level social support responses in a slow-motion technological disaster: the case of Libby, MontanaThe influence of patient expectations regarding cure on treatment decisions.Influence of clinical communication on patients' decision making on participation in clinical trials.Chronic obstructive lung diseases and risk of non-small cell lung cancer in women.The outcome of medical intensive care for lung cancer patients: the case for optimism.Primary central nervous system lymphoma in patients with and without the acquired immune deficiency syndrome. A retrospective analysis and review of the literature.Attempts to enhance locoregional control of cancer by radiotherapy, phototherapy, and combined modality therapy.Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression.Initial Outcomes of a Lung Cancer Screening Program in an Integrated Community Health System.The demonstration of cell-associated immunity to viruses. In vitro lymphocyte responsiveness to Varicella-zoster antigen.Single-agent therapy for renal cell carcinoma: CCNU, vinblastine, thioTEPA, or bleomycin.Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study.Studying the process of clinical communication: issues of context, concepts, and research directions.Herpes zoster and impaired cell-associated immunity to the varicella-zoster virus in patients with Hodgkin's disease.Use of posttreatment imaging and biomarkers in survivors of early-stage breast cancer: Inappropriate surveillance or necessary care?The multidimensional nature of cancer-related pain.A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy.The crisis of cancer: psychological impact on family caregivers.Mycoplasma contamination of membrane associated measles antigens. Inability to demonstrate in vitro lymphocyte responsiveness to measles.Physician behaviors, patient perceptions, and patient characteristics as predictors of satisfaction of hospitalized adult cancer patients.Pulmonary metastasis of basal cell carcinoma: a rare manifestation of a common disease with variable clinical course.Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.Radiation-related pericarditis.Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V--a randomized comparison of four cisplatin-containing regimens.A white blood cell RNase assay for the possible monitoring of malignancy.Suppression of in vitro lymphocyte responsiveness to purified protein derivative by measles virus. A reexploration of the phenomenon.Use of imaging for staging of early-stage breast cancer in two integrated health care systems: adherence with a choosing wisely recommendation.Unconventional style reaps rewards for Ruckdeschel. Physician executive's career carries cancer center to the forefront. Interview by Patty Ryan.Efficacy and costs of two forms of stress management training for cancer patients undergoing chemotherapy.
P50
Q28386708-61433cdd-4bfc-e494-57ee-fa0cb024413eQ33299169-2e545162-4a34-a497-9129-b97dc2ebe912Q33390775-277b56a9-4745-b415-41fb-616d108ca272Q34361329-f84993ee-40fa-bdf0-fe9d-ac121e5782b0Q34614482-a09e46c4-4952-5a8a-a75a-fa087ef6591dQ34977797-c54d54f1-4557-449e-c436-fa46b4f08ef6Q35225021-8d6d97a4-488b-e109-27e5-5d74a27b2cb2Q36070134-a833a84e-47d3-47d0-caa8-3935cba644e6Q36787634-b9c19bad-452b-78b7-fd66-26f909b9545aQ36804214-f3af18e9-4ba9-445e-32bf-1aca8e72c666Q37190056-d0b48133-4f00-0d5b-a917-a96ecd3d09d2Q37202221-c1dfd6c6-4d86-363b-dd54-ef14b8cda991Q37253723-fa1e2690-41e7-675f-704a-3e7102aa4cf7Q37350689-b0d75cdf-4e83-5981-d973-d2cfdfd6b7d7Q37832382-4658a7d8-47ec-50b1-f7cd-bb32c9fa00efQ37983863-37fe7143-4c2e-ee9b-55d4-7838ccc0245bQ38217819-afe5ec8f-4ac4-df71-5157-124f19ebff9aQ38232327-ca2c746b-4713-076c-ebc5-76b00c843ff4Q38470315-e4bf80d2-40c6-e3b9-4420-83e7e596d908Q38821805-389b0a0b-4c5c-b07a-a8e8-de7518d54b3bQ39404302-946922b1-43b4-b0e4-a9a1-60851f1658e1Q39460960-ddbc2861-44d7-a34f-91e1-b7af8fff0ca0Q39788280-a4c203e1-423a-86dc-48be-785ac07412c2Q39972353-3f25764f-456d-b07e-eba9-bc03f0951b6bQ40045460-8de387fe-48a9-b334-4011-ba5f65f1be4dQ40228943-63b1f43a-4686-b07b-77c2-13c7cd5142baQ40234589-cf65470f-4a70-6b1c-169f-e65f6bc7c429Q40648592-9d35abec-49b0-5a2f-dd4f-81e22e0bfd63Q40905795-44b5594d-47b2-76bc-13cb-82289c2d20e9Q41959477-395f3ee5-4bf2-0b46-6792-cc6a450d7963Q42113021-b5f8098c-41f1-2de8-f44e-38ccdafccd75Q42457546-6ed1a89c-4b6b-40b9-c5b5-c099886aa07dQ42745760-78dcb255-4056-7862-5f86-44ec9e4e3727Q43805942-4fd787ca-4376-9eb9-ce51-c7dea3fcc5acQ44129000-cc560d5c-4aea-fde6-c5f0-d710fbd079fbQ44984579-a517e54d-4da3-025c-0c6f-7746d3375289Q45047784-79af617a-4c56-cb39-b268-849cfc3b0507Q46114763-a101a5c8-45a7-41ff-496a-5a0251e99490Q48770531-9b1d4a31-45c0-2e30-1f03-6bc53e52db92Q51956114-53452ccc-4a72-1a4a-40cb-2fb5cddf97ec
P50
description
American oncologist
@en
oncolojiste american
@lfn
oncoloog
@nl
oncólogo estadounidense
@es
usona onkologo
@eo
name
John Ruckdeschel
@ast
John Ruckdeschel
@de
John Ruckdeschel
@en
John Ruckdeschel
@es
John Ruckdeschel
@fr
John Ruckdeschel
@ga
type
label
John Ruckdeschel
@ast
John Ruckdeschel
@de
John Ruckdeschel
@en
John Ruckdeschel
@es
John Ruckdeschel
@fr
John Ruckdeschel
@ga
altLabel
John C Ruckdeschel
@en
prefLabel
John Ruckdeschel
@ast
John Ruckdeschel
@de
John Ruckdeschel
@en
John Ruckdeschel
@es
John Ruckdeschel
@fr
John Ruckdeschel
@ga
P1006
P214
P244
P1006
P106
P1153
35847328500
P19
P21
P213
0000 0000 2710 429X
P214
P244
P31
P569
1946-01-05T00:00:00Z
P735
P7859
lccn-n87842613